Does Medicare Cover Wegovy or Ozempic for Weight Loss in 2026?

Medicare can pay for Wegovy for weight management in 2026 through the $50 Medicare GLP-1 Bridge, if you meet its eligibility rules. Ozempic is not included in the Bridge. Medicare lists the covered products and conditions.

The distinction is the prescription’s purpose. Basic Part D excludes drugs used solely for weight loss, while a GLP-1 prescribed for a covered medical indication may follow ordinary Part D rules. The Bridge operates separately, outside your drug plan’s usual benefit. HHS explains the weight-loss exclusion; CMS explains the separate Bridge.

Which Medicare coverage route fits your prescription?

The 2026 Medicare drug list includes Wegovy injection and tablets, Foundayo tablets and Zepbound KwikPen for eligible Bridge patients. Ordinary Part D uses a different set of coverage rules. This table separates the routes to check; it does not confirm that your individual prescription will be paid. Covered Bridge formulations.

Indication boundaries come from the Wegovy label, Ozempic label and FDA's Zepbound sleep-apnea approval. CMS distinguishes Part D treatment indications from Bridge weight management. A drug being eligible for Part D coverage does not guarantee it is on your plan’s formulary.

Does Medicare cover Ozempic without diabetes?

Ozempic has no approved weight-management indication. Its May 2026 US label lists three uses, all involving type 2 diabetes: blood sugar control, cardiovascular risk reduction with established cardiovascular disease, and kidney-related risk reduction with chronic kidney disease. Heart or kidney disease alone does not match those labeled uses. Ozempic prescribing information.

For a prescription solely for weight loss, basic Part D’s exclusion still matters. Calling Ozempic “semaglutide,” or seeing that Wegovy is covered, does not make the products interchangeable for insurance. Ask your prescriber and plan about the documented indication before paying for a consultation intended to obtain a particular drug. HHS Part D coverage explanation.

Does Medicare cover Wegovy for weight loss or heart disease?

Wegovy can have different coverage routes for different uses. Its June 2026 label includes weight management and cardiovascular risk reduction for eligible adults in both injection and tablet form. Injection also has an indication for certain MASH liver disease; the tablet does not. Wegovy prescribing information, section 1.

The liver indication covers adults with noncirrhotic MASH and moderate to advanced fibrosis, stages F2-F3. That indication received accelerated approval, with confirmatory evidence still required. A general diagnosis of fatty liver does not by itself establish this labeled indication. Wegovy prescribing information.

When Wegovy is prescribed for an indication coverable under Part D, CMS directs the patient to that pathway. A missing formulary entry does not automatically make the same prescription eligible for the Bridge. Ask about the plan’s coverage determination or exception process instead. CMS coverage-interaction rules.

For the separate medication-choice question, our Wegovy and Zepbound comparison explains the evidence and formulation differences to discuss with your clinician.

Who can use the $50 Medicare GLP-1 Bridge?

The Bridge requires eligible drug-plan enrollment, age 18 or older, an appropriate weight-management prescription and clinical criteria measured when GLP-1 therapy began. Its BMI thresholds are more specific than “BMI 30, or BMI 27 with any related condition.” Meeting a threshold alone is insufficient. CMS clinical criteria.

Qualifying enrollment includes a standalone PDP or an eligible Medicare Advantage coordinated-care plan with Part D, including qualifying SNP, EGWP and LI NET enrollment. Some arrangements, including PACE and private fee-for-service plans, are excluded unless you also hold an eligible standalone PDP where applicable. Your insurer does not need to opt in, and Humana's role as the processor does not require switching to a Humana plan. Use our official contact and plan-type guide or CMS's full plan-type list to check uncertain enrollment.

• •BMI 35 or higher: no additional condition is needed for this clinical threshold.
• •BMI 30 or higher: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher.
• •BMI 27 or higher: prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.

CMS defines uncontrolled hypertension here as systolic pressure above 140 or diastolic pressure above 90 despite two concurrent blood-pressure medicines. Your prescriber must verify the relevant history and ongoing nutrition and physical-activity plan. Use our Bridge guide for the detailed access process. CMS provider guidance.

Does the $50 copay count toward Part D spending?

No. The Bridge’s $50 monthly drug copay sits outside ordinary Part D: its deductible does not apply, and the payment does not move you toward your Part D out-of-pocket limit. Keep this amount separate when comparing your prescription budget with your health plan’s statements. CMS copay rules.

Medicare defines a monthly supply as 28 or 30 days, depending on the drug. Extra Help cannot lower this Bridge payment, and the Medicare Prescription Payment Plan cannot spread it across months. Clinical appointments and other services may bring separate charges, so ask the provider for those costs. Medicare cost details.

What should you ask before booking a provider?

Ask about the exact prescription and benefit before choosing a clinic. Medicare’s $50 Bridge drug payment and a provider’s own fees are separate questions, and ordinary Part D coverage may require authorization. Copy or print this checklist for your clinician, plan member-services team and pharmacy. Medicare explains the separate costs.

• •Prescription: What exact brand, formulation and treatment indication are we checking?
• •Coverage route: Is this an ordinary Part D claim or a Bridge prescription? Who confirms that route?
• •Part D requirements: Is this formulation covered for my documented indication? What authorization or formulary exception is needed?
• •Bridge requirements: Has the prescriber checked the clinical rules, excluded diagnoses and previous Part D-paid GLP-1 use?
• •Costs: What would I pay for the drug, visits, laboratory work and membership, listed separately?
• •Practical access: Which pharmacy will fill it, and who handles missing paperwork or a rejected claim?
• •Written record: Can I have the coverage decision or reference number and the next action in writing?

For ordinary drug-plan comparisons, start with Medicare Plan Compare. For a possible Bridge prescription, continue to our Medicare GLP-1 Bridge guide. Keep member numbers and medical records with your care team, pharmacy and insurer; this checklist does not require sending them to us.

What happens to Medicare GLP-1 coverage in 2027?

The Medicare GLP-1 Bridge is scheduled to continue through December 31, 2027. CMS extended it after the planned 2027 Part D launch of BALANCE did not proceed. Your insurer does not need to opt into the Bridge, so an assumed BALANCE switch is not a reason to change plans. CMS program timeline.

Some details remain unsettled. CMS has not yet specified the prior-GLP-1-use lookback period it will apply in 2027. Recheck the official rules before relying on a future eligibility decision; do not assume that the 2026 rule automatically carries forward unchanged. CMS prior-use FAQ.

Sources and verification

The original guide and US-label references were checked September 12, 2026. Medicare program, plan-type and access wording was rechecked against CMS and Medicare.gov on September 26, 2026. The matrix and checklist combine public sources; we did not verify an individual policy or submit a claim. Your clinician determines treatment suitability and the relevant payer determines coverage.